Safety and Feasibility of Additional Tumor Debulking to First-Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer.

CONCLUSION: Tumor debulking is feasible and does not prohibit administration of palliative chemotherapy in the majority of patients with multiorgan mCRC, despite the occurrence of serious adverse events related to local treatment.
IMPLICATIONS FOR PRACTICE: This first prospective randomized trial on tumor debulking in addition to chemotherapy shows that local treatment of metastases is feasible in patients with multiorgan metastatic colorectal cancer and does not prohibit administration of palliative systemic therapy, despite the occurrence of serious adverse events related to local treatment. The trial continues accrual and overall survival (OS) data and quality of life assessment are collected to determine whether the primary aim of >6 months OS benefit with preserved quality of life will be met. This will support evidence-based decision making in multidisciplinary colorectal cancer care and can be readily implemented in daily practice.
PMID: 32490570 [PubMed - as supplied by publisher]

Source: The Oncologist - June 2, 2020 Category: Cancer & Oncology Authors: Gootjes EC, van der Stok EP, Buffart TE, Bakkerus L, Labots M, Zonderhuis BM, Tuynman JB, Meijerink MR, van de Ven PM, Haasbeek CJA, Ten Tije AJ, de Groot JB, Hendriks MP, van Meerten E, Nuyttens JJME, Grunhagen DJ, Verhoef C, Verheul HMW, ORCHESTRA study Tags: Oncologist Source Type: research